Robert E. Landry - 04 Jan 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: EVP Finance CFO
Signature: /s/**Robert E. Landry
Issuer symbol: REGN
Transactions as of: 04 Jan 2024
Net transactions value: -$124,141
Form type: 4
Filing time: 08 Jan 2024, 16:02:01 UTC
Previous filing: 04 Jan 2024
Next filing: 17 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise	$189,490	+500	+2.2%	$378.98	22,948	04 Jan 2024	Direct
transaction	REGN	Common Stock	Tax liability	$313,631	-342	-1.5%	$917.05	22,606	04 Jan 2024	Direct
holding	REGN	Common Stock						270	04 Jan 2024	By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-500	-3.1%	$0.000000	15,487	04 Jan 2024	Common Stock	500	$378.98	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award vests in four equal annual installments, commencing one year after the date of grant.